Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2021
Cystic fibrosis patients upset over recommended restrictive criteria for life saving drug
15 July 2021 - 'By narrowly defining accessibility and continuation criteria CADTH’s recommendation overlooks many of Trikafta’s significant benefits,' says chief ...
Posted by Michael Wonder on 13 Jul 2021
'A price on your life': Toronto cystic fibrosis patients slam review process while waiting for access to life-saving treatment
13 July 2021 - While Health Canada approved Trikafta for patient use on June 18, 2021, it is still not ...
Posted by Michael Wonder on 11 Feb 2021
Cystic fibrosis advocate asks P.E.I. to fast-track coverage of new 'mind-blowing' drug
10 February 2021 - ‘It’s the closest thing we’ve ever had to a cure’. ...
Posted by Michael Wonder on 10 Nov 2020
Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug
10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...
Posted by Michael Wonder on 01 Nov 2020
CADTH recommends new treatment option for patients with plaque psoriasis
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
Posted by Michael Wonder on 20 Aug 2020
Life saving cystic fibrosis drug still unavailable in Canada
19 August 2020 - Nicole Stringer has been meeting with surgeons about the possibility of having a double-lung transplant. The ...
Posted by Michael Wonder on 10 Dec 2019
Pickering mom fights for life-changing CF medicine to come to Canada
10 December 2019 - Stephanie Stavros feels like she's 'screaming into an abyss' as her life slips away. ...
Posted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...
Posted by Michael Wonder on 04 Dec 2018
Enstilar is now covered by the Alberta Drug Benefit List for adults with psoriasis vulgaris
3 December 2018 - Leo Pharma Canada has announced that as of 1 December 2018, Enstilar has been added as ...
Posted by Michael Wonder on 08 Oct 2018
Committee recommends against funding $250,000-a-year Orkambi cystic fibrosis drug
4 October 2018 - Canadian governments should not pay for a $250,000-a-year cystic fibrosis medication because it is not clear ...
Posted by Michael Wonder on 24 Jul 2018
Cystic fibrosis patients launch class-action suit over access to costly drug
24 July 2018 - A young Victoria woman with cystic fibrosis who fought to get coverage of a life-changing drug ...
Posted by Michael Wonder on 22 May 2018
Okanagan MLA pushes province, drug company to provide compassionate coverage for pricey drug
22 May 2018 - It’s been more than four months since a Vernon woman with cystic fibrosis was forced to ...
Posted by Michael Wonder on 10 May 2018
CF Canada launches campaign to make Orkambi accessible to more patients
9 May 2018 - Cystic Fibrosis Canada launched a national campaign in May, which is Cystic Fibrosis Awareness Month, to ...
Posted by Michael Wonder on 20 Mar 2018
B.C. woman receives long-term supply of life-saving drug — but vows to fight for coverage for all
19 March 2018 - 'I have the energy to fight for more than just my life'. ...
Posted by Michael Wonder on 07 Feb 2018
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Maviret – an oral therapy for the treatment of patients with hepatitis C
6 February 2018 - Maviret previously received a Notice of Compliance from Health Canada on 16 August 2017. ...